Reviva Pharmaceuticals Holdings, Inc.
9.2M
$2.89M
-2.01
$-18.05
No price alerts set. Add an alert to get notified!
-2.01
73.84
$-18.05
-3,681.99%
0.00%
0.00%
Compare TSM with similar companies in the sector
| Company | Price | Change % | P/E | Market Cap | D/E |
|---|---|---|---|---|---|
|
ANVS
Annovis Bio, Inc.
|
$2.60 | 5.06% | -2.23 | $51.05M | 0.00 |
|
ATNM
Actinium Pharmaceuticals, Inc.
|
$1.09 | -1.36% | -0.98 | $33.85M | 0.08 |
|
BCAB
BioAtla, Inc.
|
$0.16 | -0.75% | -0.14 | $9.29M | -0.20 |
|
BTAI
BioXcel Therapeutics, Inc.
|
$1.60 | -3.04% | -0.33 | $35.10M | -1.23 |
|
CELU
Celularity Inc.
|
$1.29 | 2.80% | -0.42 | $30.91M | -3.32 |
|
EVAX
Evaxion Biotech A/S
|
$3.85 | 1.85% | -3.19 | $24.60M | 0.44 |
|
FGEN
FibroGen, Inc.
|
$9.07 | -1.63% | 0.16 | $36.69M | 0.00 |
|
PDSB
PDS Biotechnology Corporation
|
$0.61 | -6.76% | -0.81 | $33.14M | 1.90 |
|
PYPD
PolyPid Ltd.
|
$4.33 | -1.37% | -2.61 | $44.13M | 0.25 |
|
TVRD
Tvardi Therapeutics, Inc.
|
$3.69 | 7.12% | -2.48 | $34.57M | 0.01 |
* Peer stocks are selected based on market capitalization and sector
$23.40
$0.67
$0.00
0.00%
Reviva Pharmaceuticals Holdings, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, cardiovascular, metabolic, and inflammatory diseases. The company's lead product candidate is RP5063, which is in Phase III clinical trials for the treatment of schizophrenia, as well as completed Phase I clinical trials to treat bipolar disorder, major depressive disorder, attention–deficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer's disease, Parkinson's disease psychosis, attention deficit hyperactivity disorder, pulmonary arterial hypertension, and idiopathic pulmonary fibrosis. It is also developing RP1208 that is in pre-clinical development studies for the treatment of depression and obesity. The company is headquartered in Cupertino, California.
